OGS continues merger discussions

Published: 24-Mar-2003

Oxford GlycoSciences is continuing merger discussions both with Cambridge Antibody Technology Group (CAT) and other potentially interested third parties.


Oxford GlycoSciences is continuing merger discussions both with Cambridge Antibody Technology Group (CAT) and other potentially interested third parties.

'There is still all to play for. We remain in active discussions with CAT with a view to obtaining a material improvement in the value of their offer,' said ceo Dr David Ebsworth. 'In addition, we continue to seek further offers from other potentially interested parties.'

You may also like